Companies › Immunomic Therapeutics
2 active drug programs in 2 registered trials: 2 Phase 1; Immunology, Oncology; next expected readout Feb 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ITI-5000 Self-amplifying RNA vaccine targeting HERV-K and CT83 fused with LAMP-1 | HERVK, CT83, LAMP1 | Phase 1 | Triple Negative Breast Cancer (TNBC) | Feb 2028 |
| ITI-9001 self-amplifying RNA (saRNA) immunotherapy encoding CryJ2-LAMP-1 fusion protein | – | Phase 1 | Allergen Immunotherapy | Feb 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07726147 | ITI-9001 | Phase 1 | Allergen Immunotherapy | Immunology | Feb 2028 |
| NCT07652242 | ITI-5000 | Phase 1 | Triple Negative Breast Cancer (TNBC) | Oncology | Feb 2028 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.